Contact system revisited: An interface between inflammation, coagulation, and innate immunity

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 3, 2016, Pages 427-437

  Long, A T ^a   Kenne, E ^b   Jung, R ^a   Fuchs, T A ^a,b   Renne T ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Angioedema; Anticoagulation; Factor XII; Inflammation; Polyphosphates; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; POLYPHOSPHATE; AUTACOID; BLOOD CLOTTING FACTOR 12;

ALLERGIC REACTION; ANGIONEUROTIC EDEMA; BLOOD CLOTTING; HOST RESISTANCE; HUMAN; IN VIVO STUDY; INFLAMMATION; INNATE IMMUNITY; LIVER CELL; NONHUMAN; PLASMA CONTACT SYSTEM; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; THROMBOSIS; ANIMAL; BLOOD; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANGIOEDEMAS, HEREDITARY; ANIMALS; BLOOD COAGULATION; FACTOR XII; HEPATOCYTES; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; INFLAMMATION; INFLAMMATION MEDIATORS; POLYPHOSPHATES; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84959916599     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13235     Document Type: Review

References (100)

1. Renne T. The procoagulant and proinflammatory plasma contact system. Semin Immunopathol 2012; 34: 31-41.
2. Maas C, Oschatz C, Renne T. The plasma contact system 2.0. Semin Thromb Hemost 2011; 37: 375-81.
3. Muller F, Renne T. Novel roles for factor XII-driven plasma contact activation system. Curr Opin Hematol 2008; 15: 516-21.
4. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacol Rev 2005; 57: 27-77.
5. Renne T, Dedio J, David G, Muller-Ester W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J Biol Chem 2000; 275: 33688-96.
6. Renne T, Muller-Esterl W. Cell surface-associated chondroitin sulfate proteoglycans bind contact phase factor H-kininogen. FEBS Lett 2001; 500: 36-40.
7. Henderson LM, Figueroa CD, Muller-Esterl W, Bhoola KD. Assembly of contact-phase factors on the surface of the human neutrophil membrane. Blood 1994; 84: 474-82.
8. Colman RW. Activation of plasminogen by human plasma kallikrein. Biochem Biophys Res Commun 1969; 35: 273-9.
9. Bjorkqvist J, Nickel KF, Stavrou E, Renne T. In vivo activation and functions of the protease factor XII. Thromb Haemost 2014; 112: 868-75.
10. Khan S, Dickerman JD. Hereditary thrombophilia. Thromb J 2006; 4: 15.
11. Schapira M, Ramus MA, Jallat S, Carvallo D, Courtney M. Recombinant alpha 1-antitrypsin pittsburgh (Met 358-Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment. J Clin Invest 1986; 77: 635-7.
12. LaRusch GA, Mahdi F, Shariat-Madar Z, Adams G, Sitrin RG, Zhang WM, McCrae KR, Schmaier AH. Factor XII stimulates Erk1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 2010; 115: 5111-20.
13. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 119-21.
14. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
15. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D, Nieswandt B. Defective thrombus formation in mice lacking coagulation factor XII. J Exp Med 2005; 202: 271-81.
16. Ratnoff OD, Colopy JE. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma. J Clin Invest 1955; 34: 602-13.
17. Peyvandi F, Palla R, Menegatti M, Siboni SM, Halimeh S, Faeser B, Pergantou H, Platokouki H, Giangrande P, Peerlinck K, Celkan T, Ozdemir N, Bidlingmaier C, Ingerslev J, Giansily-Blaizot M, Schved JF, Gilmore R, Gadisseur A, Benedik-Dolnicar M, Kitanovski L, et al.; European Network of Rare Bleeding Disorders Group. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost 2012; 10: 615-21.
18. Pathak M, Wilmann P, Awford J, Li C, Fischer PM, Dreveny I, Dekker LV, Emsley J. Coagulation factor XII protease domain crystal structure. J Thromb Haemost 2015; 13: 580-91.
19. Engel R, Brain CM, Paget J, Lionikiene AS, Mutch NJ. Single-chain factor XII exhibits activity when complexed to polyphosphate. J Thromb Haemost 2014; 12: 1513-22.
20. Hovinga JK, Schaller J, Stricker H, Wuillemin WA, Furlan M, Lammle B. Coagulation factor XII Locarno: the functional defect is caused by the amino acid substitution Arg 353->Pro leading to loss of a kallikrein cleavage site. Blood 1994; 84: 1173-81.
21. Wuillemin WA, Furlan M, Stricker H, Lammle B. Functional characterization of a variant factor XII (F XII Locarno) in a cross reacting material positive F XII deficient plasma. Thromb Haemost 1992; 67: 219-25.
22. Monroe DM, Mackman N, Hoffman M. Wound healing in hemophilia B mice and low tissue factor mice. Thromb Res 2010; 125(Suppl. 1): S74-7.
23. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler Thromb Vasc Biol 2004; 24: 1015-22.
24. Iwaki T, Castellino FJ. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb Haemost 2006; 95: 1003-10.
25. Pauer HU, Renne T, Hemmerlein B, Legler T, Fritzlar S, Adham I, Muller-Esterl W, Emons G, Sancken U, Engel W, Burfeind P. Targeted deletion of murine coagulation factor XII gene - a model for contact phase activation in vivo. Thromb Haemost 2004; 92: 503-8.
26. Revenko AS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, Gailani D, Monia BP, MacLeod AR. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 2011; 118: 5302-11.
27. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun MF, White-Adams TC, Smith SA, Hanson SR, McCarty OJ, Renne T, Gruber A, Gailani D. A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 2010; 116: 3981-9.
28. van der Meijden PE, Munnix IC, Auger JM, Govers-Riemslag JW, Cosemans JM, Kuijpers MJ, Spronk HM, Watson SP, Renne T, Heemskerk JW. Dual role of collagen in factor XII-dependent thrombus formation. Blood 2009; 114: 881-90.
29. Maas C, Govers-Riemslag JW, Bouma B, Schiks B, Hazenberg BP, Lokhorst HM, Hammarstrom P, ten Cate H, de Groot PG, Bouma BN, Gebbink MF. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J Clin Invest 2008; 118: 3208-18.
30. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D, Massberg S, Gunther A, Engelmann B, Preissner KT. Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulation. Proc Natl Acad Sci USA 2007; 104: 6388-93.
31. Smith SA, Mutch NJ, Baskar D, Rohloff P, Docampo R, Morrissey JH. Polyphosphate modulates blood coagulation and fibrinolysis. Proc Natl Acad Sci USA 2006; 103: 903-8.
32. Rao NN, Gomez-Garcia MR, Kornberg A. Inorganic polyphosphate: essential for growth and survival. Annu Rev Biochem 2009; 78: 605-47.
33. Pejler G, Karlstrom A. Thrombin is inactivated by mast cell secretory granule chymase. J Biol Chem 1993; 268: 11817-22.
34. Peerschke EI, Ghebrehiwet B. Human blood platelet gc1qR/p33. Immunol Rev 2001; 180: 56-64.
35. Peerschke EI, Bayer AS, Ghebrehiwet B, Xiong YQ. gc1qR/p33 blockade reduces Staphylococcus aureus colonization of target tissues in an animal model of infective endocarditis. Infect Immun 2006; 74: 4418-23.
36. Tchougounova E, Pejler G, Abrink M. The chymase, mouse mast cell protease 4, constitutes the major chymotrypsin-like activity in peritoneum and ear tissue. A role for mouse mast cell protease 4 in thrombin regulation and fibronectin turnover. J Exp Med 2003; 198: 423-31.
37. Ruiz FA, Lea CR, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes. J Biol Chem 2004; 279: 44250-7.
38. Muller F, Mutch NJ, Schenk WA, Smith SA, Esterl L, Spronk HM, Schmidbauer S, Gahl WA, Morrissey JH, Renne T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139: 1143-56.
39. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, Esmon CT. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood 2011; 118: 1952-61.
40. Nickel KF, Spronk HM, Mutch NJ, Renne T. Time-dependent degradation and tissue factor addition mask the ability of platelet polyphosphates in activating factor XII-mediated coagulation. Blood 2013; 122: 3847-9.
41. Ghosh S, Shukla D, Suman K, Lakshmi BJ, Manorama R, Kumar S, Bhandari R. Inositol hexakisphosphate kinase 1 maintains hemostasis in mice by regulating platelet polyphosphate levels. Blood 2013; 122: 1478-86.
42. Smith SA, Morrissey JH. Comment on Faxalv et al. "Putting polyphosphates to the test: evidence against platelet-induced activation of factor XII". Blood 2013; 122.
43. Smith SA, Choi SH, Davis-Harrison R, Huyck J, Boettcher J, Rienstra CM, Morrissey JH. Polyphosphate exerts differential effects on blood clotting, depending on polymer size. Blood 2010; 116: 4353-9.
44. Puy C, Tucker EI, Wong ZC, Gailani D, Smith SA, Choi SH, Morrissey JH, Gruber A, McCarty OJ. Factor XII promotes blood coagulation independent of factor XI in the presence of long-chain polyphosphates. J Thromb Haemost 2013; 11: 1341-52.
45. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood 2011; 118: 6963-70.
46. Montilla M, Hernandez-Ruiz L, Garcia-Cozar FJ, Alvarez-Laderas I, Rodriguez-Martorell J, Ruiz FA. Polyphosphate binds to human von Willebrand factor in vivo and modulates its interaction with glycoprotein Ib. J Thromb Haemost 2012; 10: 2315-23.
47. Choi SH, Smith SA, Morrissey JH. Polyphosphate accelerates factor V activation by factor XIa. Thromb Haemost 2014; 113: 599-604.
48. Konings J, Govers-Riemslag JW, Philippou H, Mutch NJ, Borissoff JI, Allan P, Mohan S, Tans G, Ten Cate H, Ariens RA. Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 2011; 118: 3942-51.
49. Zucker M, Seligsohn U, Salomon O, Wolberg AS. Abnormal plasma clot structure and stability distinguish bleeding risk in patients with severe factor XI deficiency. J Thromb Haemost 2014; 12: 1121-30.
50. Smith SA, Morrissey JH. Polyphosphate enhances fibrin clot structure. Blood 2008; 112: 2810-6.
51. Baglia FA, Gailani D, Lopez JA, Walsh PN. Identification of a binding site for glycoprotein Ibalpha in the Apple 3 domain of factor XI. J Biol Chem 2004; 279: 45470-6.
52. Zakharova NV, Artemenko EO, Podoplelova NA, Sveshnikova AN, Demina IA, Ataullakhanov FI, Panteleev MA. Platelet surface-associated activation and secretion-mediated inhibition of coagulation factor XII. PLoS ONE 2015; 10: e0116665.
53. Travers RJ, Shenoi RA, Kalathottukaren MT, Kizhakkedathu JN, Morrissey JH. Nontoxic polyphosphate inhibitors reduce thrombosis while sparing hemostasis. Blood 2014; 124: 3183-90.
54. Hojima Y, Cochrane CG, Wiggins RC, Austen KF, Stevens RL. Invitro activation of the contact (Hageman-factor) system of plasma by heparin and chondroitin sulfate-E. Blood 1984; 63: 1453-9.
55. Wernersson S, Pejler G. Mast cell secretory granules: armed for battle. Nat Rev Immunol 2014; 14: 478-94.
56. Colman RF, Chu R. Deuterium solvent isotope effects in reactions catalyzed. Biochem Biophys Res Commun 1969; 34: 528-35.
57. Sala-Cunill A, Bjorkqvist J, Senter R, Guilarte M, Cardona V, Labrador M, Nickel KF, Butler L, Luengo O, Kumar P, Labberton L, Long A, Di Gennaro A, Kenne E, Jamsa A, Krieger T, Schluter H, Fuchs T, Flohr S, Hassiepen U, et al. Plasma contact system activation drives anaphylaxis in severe mast cell-mediated allergic reactions. J Allergy Clin Immunol 2014; 135: 1031-43.
58. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, Sedlmeier R, Burfeind P, Cichon S, Hammerschmidt S, Muller-Esterl W, Wuillemin WA, Nilsson G, Renne T. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 2011; 34: 258-68.
59. Iwaki T, Cruz-Topete D, Castellino FJ. A complete factor XII deficiency does not affect coagulopathy, inflammatory responses, and lethality, but attenuates early hypotension in endotoxemic mice. J Thromb Haemost 2008; 6: 1993-5.
60. Kauhanen P, Kovanen PT, Lassila R. Coimmobilized native macromolecular heparin proteoglycans strongly inhibit platelet-collagen interactions in flowing blood. Arterioscler Thromb Vasc Biol 2000; 20: E113-9.
61. Bjorkqvist J, Jamsa A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost 2013; 110: 399-407.
62. Coffman LG, Brown JC, Johnson DA, Parthasarathy N, D'Agostino RB Jr, Lively MO, Hua X, Tilley SL, Muller-Esterl W, Willingham MC, Torti FM, Torti SV. Cleavage of high-molecular-weight kininogen by elastase and tryptase is inhibited by ferritin. Am J Physiol Lung Cell Mol Physiol 2008; 294: L505-15.
63. Dobo J, Major B, Kekesi KA, Szabo I, Megyeri M, Hajela K, Juhasz G, Zavodszky P, Gal P. Cleavage of kininogen and subsequent bradykinin release by the complement component: mannose-binding lectin-associated serine protease (MASP)-1. PLoS ONE 2011; 6: e20036.
64. Lindsay SL, Ramsey S, Aitchison M, Renne T, Evans TJ. Modulation of lamellipodial structure and dynamics by NO-dependent phosphorylation of VASP Ser239. J Cell Sci 2007; 120: 3011-21.
65. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981; 153: 665-76.
66. Taylor SL, Wahl-Jensen V, Copeland AM, Jahrling PB, Schmaljohn CS. Endothelial cell permeability during hantavirus infection involves factor XII-dependent increased activation of the kallikrein-kinin system. PLoS Pathog 2013; 9: e1003470.
67. Gershom ES, Sutherland MR, Lollar P, Pryzdial EL. Involvement of the contact phase and intrinsic pathway in herpes simplex virus-initiated plasma coagulation. J Thromb Haemost 2010; 8: 1037-43.
68. Loof TG, Deicke C, Medina E. The role of coagulation/fibrinolysis during Streptococcus pyogenes infection. Front Cell Infect Microbiol 2014; 4: 128.
69. Frick IM, Bjorck L, Herwald H. The dual role of the contact system in bacterial infectious disease. Thromb Haemost 2007; 98: 497-502.
70. Nickel KF, Renne T. Crosstalk of the plasma contact system with bacteria. Thromb Res 2012; 130(Suppl. 1): S78-83.
71. Herwald H, Morgelin M, Olsen A, Rhen M, Dahlback B, Muller-Esterl W, Bjorck L. Activation of the contact-phase system on bacterial surfaces - a clue to serious complications in infectious diseases. Nat Med 1998; 4: 298-302.
72. Imamura T, Potempa J, Pike RN, Travis J. Dependence of vascular permeability enhancement on cysteine proteinases in vesicles of Porphyromonas gingivalis. Infect Immun 1995; 63: 1999-2003.
73. Mattsson E, Herwald H, Cramer H, Persson K, Sjobring U, Bjorck L. Staphylococcus aureus induces release of bradykinin in human plasma. Infect Immun 2001; 69: 3877-82.
74. Frick IM, Akesson P, Herwald H, Morgelin M, Malmsten M, Nagler DK, Bjorck L. The contact system - a novel branch of innate immunity generating antibacterial peptides. EMBO J 2006; 25: 5569-78.
75. Sun H, Wang X, Degen JL, Ginsburg D. Reduced thrombin generation increases host susceptibility to group a streptococcal infection. Blood 2009; 113: 1358-64.
76. Sonesson A, Nordahl EA, Malmsten M, Schmidtchen A. Antifungal activities of peptides derived from domain 5 of high-molecular-weight kininogen. Int J Pept 2011; 2011: 761037.
77. Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care 2014; 2: 67.
78. Hothorn M, Neumann H, Lenherr ED, Wehner M, Rybin V, Hassa PO, Uttenweiler A, Reinhardt M, Schmidt A, Seiler J, Ladurner AG, Herrmann C, Scheffzek K, Mayer A. Catalytic core of a membrane-associated eukaryotic polyphosphate polymerase. Science 2009; 324: 513-6.
79. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-5.
80. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 2010; 107: 15880-5.
81. Pavlov V, Zorn M, Kramer R. Probing single-stranded DNA and its biomolecular interactions through direct catalytic activation of factor XII, a protease of the blood coagulation cascade. Biochem Biophys Res Commun 2006; 349: 1011-5.
82. Jain S, Pitoc GA, Holl EK, Zhang Y, Borst L, Leong KW, Lee J, Sullenger BA. Nucleic acid scavengers inhibit thrombosis without increasing bleeding. Proc Natl Acad Sci USA 2012; 109: 12938-43.
83. Gob E, Reymann S, Langhauser F, Schuhmann MK, Kraft P, Thielmann I, Gobel K, Brede M, Homola G, Solymosi L, Stoll G, Geis C, Meuth SG, Nieswandt B, Kleinschnitz C. Blocking of plasma kallikrein ameliorates stroke by reducing thromboinflammation. Ann Neurol 2015; 77: 784-803.
84. Kotronen A, Joutsi-Korhonen L, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, Lundbom N, Rissanen A, Lassila R, Yki-Jarvinen H. Increased coagulation factor VIII, IX, XI and XII activities in non-alcoholic fatty liver disease. Liver Int 2011; 31: 176-83.
85. Farsetti A, Moretti F, Narducci M, Misiti S, Nanni S, Andreoli M, Sacchi A, Pontecorvi A. Orphan receptor hepatocyte nuclear factor-4 antagonizes estrogen receptor alpha-mediated induction of human coagulation factor XII gene. Endocrinology 1998; 139: 4581-9.
86. Inoue Y, Peters LL, Yim SH, Inoue J, Gonzalez FJ. Role of hepatocyte nuclear factor 4alpha in control of blood coagulation factor gene expression. J Mol Med (Berl) 2006; 84: 334-44.
87. Sabater-Lleal M, Chillon M, Mordillo C, Martinez A, Gil E, Mateo J, Blangero J, Almasy L, Fontcuberta J, Soria JM. Combined cis-regulator elements as important mechanism affecting FXII plasma levels. Thromb Res 2010; 125: e55-60.
88. Bjorkqvist J, Sala-Cunill A, Renne T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb Haemost 2013; 109: 368-74.
89. Han ED, MacFarlane RC, Mulligan AN, Scafidi J, Davis AE. Increased vascular permeability in C1 men inhibitor-deficient mice mediated by the bradykinin type 2 receptor. J Clin Invest 2002; 109: 1057-63.
90. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356: 213-7.
91. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343: 1286-9.
92. Baeza ML, Rodriguez-Marco A, Prieto A, Rodriguez-Sainz C, Zubeldia JM, Rubio M. Factor XII gene missense mutation Thr328Lys in an Arab family with hereditary angioedema type III. Allergy 2011; 66: 981-2.
93. Cichon S, Martin L, Hennies HC, Mueller F, van Driessche K, Karpushova A, Stevens W, Colombo R, Renne T, Drouet C, Bork K, Nothen MM. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006; 79: 1098-104.
94. Björkqvist J, de Maat S, Lewandrowski U, Di Gennaro A. Oschatz C, Schönig K, Nöthen MM, Drouet C, Braley H, Nolte MW, Sickmann A, Panousis C, Maas C, and Renné T, Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J Clin Invest 2015; 25: 3132-46.
95. Joseph K, Tholanikunnel BG, Wolf B, Bork K, Kaplan AP. Deficiency of plasminogen activator inhibitor 2 in plasma of patients with hereditary angioedema with normal C1 inhibitor levels. J Allergy Clin Immunol 2015. doi:10.1016/j.jaci.2015.07.041
96. Maas C, Renne T. Regulatory mechanisms of the plasma contact system. Thromb Res 2012; 129(Suppl. 2): S73-6.
97. Renne T, Schmaier AH, Nickel KF, Blomback M, Maas C. In vivo roles of factor XII. Blood 2012; 120: 4296-303.
98. Bock PE, Srinivasan KR, Shore JD. Activation of intrinsic blood coagulation by ellagic acid: insoluble ellagic acid-metal ion complexes are the activating species. Biochemistry 1981; 20: 7258-66.
99. van der Meijden PE, van Schilfgaarde M, van Oerle R, Renne T, ten Cate H, Spronk HM. Platelet- and erythrocyte-derived microparticles trigger thrombin generation VIa factor XIIa. J Thromb Haemost 2012; 10: 1355-62.
100. Nickel KF, Ronquist G, Langer F, Labberton L, Fuchs TA, Bokemeyer C, Sauter G, Graefen M, Mackman N, Stavrou EX, Ronquist G, Renné T. The polyphosphate-factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood 2015; 126: 1379-89.